checkAd

     365  0 Kommentare BioNxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement

    NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / June 19, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce …

    NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

    VANCOUVER, BC / ACCESSWIRE / June 19, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that, further to its news releases dated April 25, 2024, and May 10, 2024, the Company has closed the second tranche of its non-brokered private placement in the amount of 1,000,000 common shares in the capital of the Company (each, a "Common Share") at a price of $0.27 per Common Share for gross proceeds of $270,000 (the "Second Tranche"). The total placement size, cumulative of all tranches, is anticipated to be a maximum of 6,000,000 Common Shares for maximum gross proceeds of $1,620,000 (the "Offering"). The Company intends to close one or more tranches of the Offering in the future.

    The Company intends to use the net proceeds from the Offering, including the Second Tranche, for research, development, commercialization programs, and general working capital purposes.

    In connection with closing of the Second Tranche, the Company paid cash finder's fees in the amount of $21,600 to an eligible finder, and issued to the same finder 80,000 non-transferable Common Share purchase warrants (the "Finder's Warrants"), with each Finder's Warrant exercisable into a Share for a period of 24 months from the date of issuance at a price of $0.36 per Common Share.

    All securities issued in connection with closing of the Second Tranche are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.

    The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities.

    About BioNxt Solutions Inc.

    BioNxt Solutions Inc. is a bioscience accelerator focused on next‐generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low‐cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets

    Seite 1 von 2



    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen
    Verfasst von Accesswire
    BioNxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / June 19, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce …